Source: CureToday articles
Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer.
Recent Content
- IDSA Guideline Recommendations: Treating Multi-Drug Resistant and Difficult to Treat Resistant P. aeruginosa
- Rina-S Yields 50% Response Rate in Advanced Endometrial Cancer
- ASCO 2025: Adding Carboplatin Did Not Result in Statistically Significant Improvements in Patients With TNBC
- Maximizing Your Pharmacy Fellowship Experience: Tips for Success
- Addressing Unmet Needs for Young Women Before, During and After a Cancer Diagnosis
- ASCO 2025 Delivers Insights into Future of Myelofibrosis Care
- S2. Ep 56: Insights from a Pharmacy Times Peer Exchange: How to Talk the Talk
- Day 5: Top Takeaways From ASCO25
- Expert Q&A: Pharmacist-Led Strategies to Improve Cholesterol Management
- Camber Pharmaceuticals Announces Addition of Olmesartan Medoxomil Tablets, USP